SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) May 11, 2000
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that its
subsidiary IDT, Inc., a leading developer of
extracorporeal hyperthermia medical devices, has
changed its corporate name to ViaCirQ, Inc. The name
change better identifies the new corporate mission of
ViaCirQ, which is to provide innovations in thermal
therapy via the ThermoChem technology.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: May 11, 2000
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL TECHNOLOGY SUBSIDIARY, IDT, INC.
CHANGES CORPORATE NAME TO ViaCirQ
Pittsburgh, PA (May 11, 2000) - Biocontrol Technology, Inc.
(OTCBB:BICO) announced today that its subsidiary IDT, Inc., a
leading developer of extracorporeal hyperthermia medical devices,
has changed its corporate name to ViaCirQ, Inc.
From the inception of the company in 1992, all activities
have focused on the research and development of the ThermoChem
technology to support safe hyperthermia therapies.
The name change better identifies the new corporate mission
of ViaCirQ, which is to provide innovations in thermal therapy
via the ThermoChem technology.
ViaCirQ has developed and received FDA Clearance for the
ThermoChem-HT SystemT for intraperitoneal hyperthermia where the
core temperature of the peritoneum is raised to the desired
targeted temperature in the 41 C (105.8 F) to 42 C (107.6 F)
range by continuously lavaging the peritoneum with circulating
sterile solution.
Intraperitoneal hyperthermia is used as an adjunct therapy
with surgery and chemotherapy in the treatment of advanced
ovarian and gastrointestinal cancer.
ViaCirQ has begun the process of integrating and
implementing its quality system in order to meet the regulatory
requirements for operation to the quality system regulations of
the United States Food and Drug Administration and the European
Community certification for ISO 9001 and EN46001.
- more -
Biocontrol has its corporate offices in Pittsburgh, Pa. and
is involved in the development and manufacture of biomedical
devices and environmental products. ViaCirQ, Inc., a subsidiary
of Biocontrol also located in Pittsburgh, Pa., holds exclusive
worldwide marketing rights to the ThermoChem technology and
related disposables for regional and whole body hyperthermia.
WEB SITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204
This press release contains statements of a forward-looking
nature. Shareholders and potential investors are cautioned
that such statements are predictions and actual events or results
may vary significantly.
###